CDC20基因的表达对前列腺癌患者临床病理特征及预后的影响

Effect of cell division cycle gene 20 expression on clinicopathological characteristics and prognosis of prostate cancer patients

目的分析细胞分裂周期基因20(CDC20)在前列腺癌(PC)组织中的表达及其对前列腺癌患者临床病理特征和预后的影响。方法收集2016年1月-2018年12月在联勤保障部队第988医院进行手术治疗的134例PC患者的PC组织,以及134例良性前列腺增生患者的良性前列腺增生组织。采用qRT-PCR、Western blotting和免疫组化检测CDC20在PC组织及良性前列腺增生组织中的表达情况。根据免疫组化评分将PC患者分为CDC20高表达组(n=69)与CDC20低表达组(n=65),比较两组患者的临床病理特征、3年总生存率和疾病无进展生存率。采用Cox回归分析影响患者术后生存的危险因素。结果qRT-PCR和Western blotting检测结果显示,PC组织中CDC20 mRNA和蛋白相对表达水平高于良性前列腺增生组织,差异有统计学意义(mRNA:1.96±0.34 vs.0.37±0.12,P=0.003;蛋白:1.02±0.08 vs.0.15±0.06,P<0.001)。免疫组化检测结果显示,PC组织中CDC20阳性表达率和高表达率高于良性前列腺增生组织[CDC20阳性表达率:80.6%(108/134)vs.8.9%(12/134),P<0.001;CDC20高表达率:51.5%(69/134)vs.0.0%(0/134),P<0.001]。CDC20高表达组术后3年总生存率、疾病无进展生存率低于CDC20低表达组[3年总生存率:69.6%(48/69)vs.87.7%(57/65),P=0.012;3年疾病无进展生存率:62.3%(43/69)vs.80.0%(52/65),P=0.020],差异有统计学意义。Gleason评分>7分、cT分期>cT_(2c)期、T分期>T2期和CDC20免疫组化评分≥8分是影响PC患者术后生存的独立危险因素(P<0.05)。结论CDC20在PC组织中表达增加,可能参与了肿瘤的进展。CDC20免疫组化评分≥8分提示患者预后不良,有望成为判断PC预后的肿瘤标志物。

Objective To detect the expression level of cell division cycle gene 20(CDC20)in prostate cancer(PC)tissues and analyze the effect on the clinicopathological characteristics and prognosis of PC patients.Methods To collect the prostatic tissues of 134 PC patients and benign prostate hyperplasia tissues of 134 patients with benign prostate hyperplasia who underwent surgical treatment in the 988th Hospital of Joint Logistics Support Force from January 2016 to December 2018.qRT-PCR,Western blotting and immunohistochemical method were used to detect the expression of CDC20 in PC tissues and benign prostate hyperplasia tissues.According to the immunohistochemical score,the PC patients were divided into CDC20 high expression group(n=69)and CDC20 low expression group(n=65).The clinicopathological characteristics,3-year overall survival rate and disease progression-free survival rate were compared between the two groups.Cox regression analysis were performed to analyze the risk factors affecting the survival of patients after surgery.Results The results of qRT-PCR and Western blotting showed that the relative expression levels of CDC20 mRNA and protein were higher in PC tissues than in benign prostate hyperplasia tissues with statistically significant difference(mRNA:1.96±0.34 vs.0.37±0.12,P=0.003;protein:1.02±0.08 vs.0.15±0.06,P<0.001).The immunohistochemical test results showed that the positive expression rate and high expression rate of CDC20 were higher in PC tissues than in benign prostate hyperplasia tissues[CDC20 positive expression rate:80.6%(108/134)vs.8.9%(12/134),P<0.001;CDC20 high expression rate:51.5%(69/134)vs.0.0%(0/134),P<0.001].The 3-year overall survival rate and disease progression-free survival rate were lower in CDC20 high expression group than in CDC20 low expression group with statistically significant difference[3-year overall survival rate:69.6%(48/69)vs.87.7%(57/65),P=0.012;3-year disease progression-free survival rate:62.3%(43/69)vs.80.0%(52/65),P=0.020].Gleason score>7 points,cT stage>cT_(2c) stage,T stage>T2 stage,and CDC20 immunohistochemical score≥8 points were independent risk factors affecting postoperative survival of PC patients(P<0.05).Conclusions The increased expression of CDC20 in PC tissue might mean the progress of PC.CDC20 immunohistochemical score≥8 points suggests a poor prognosis for patients,so is expected to become a tumor marker for judging the prognosis of PC.